Monoclonal Antibodies Stocks List Ranked for 2024

Symbol	Grade	Name	% Change
IFRX	F	InflaRx N.V.	0.00
GLPG	F	Galapagos NV	-1.34
VCNX	F	Vaccinex, Inc.	0.00
ARDS	F	Aridis Pharmaceuticals Inc.	0.00
MGNX	F	MacroGenics, Inc.	1.50
BNOX	F	Bionomics Limited	11.26
OTLK	F	Outlook Therapeutics, Inc.	-1.76
IVVD	F	Invivyd, Inc.	0.22
SLRN	F	Acelyrin Inc.	2.79
BDX	F	Becton, Dickinson and Company	-0.18

Symbol	Grade	Name	Weight
IHI	D	iShares U.S. Medical Devices ETF	4.6
EQTY	B	Kovitz Core Equity ETF	4.14
CFCV	A	ClearBridge Focus Value ETF	2.88
YLDE	B	ClearBridge Dividend Strategy ESG ETF	2.78
MDEV	C	First Trust Indxx Medical Devices ETF	1.96

Compare ETFs

Date	Stock	Title
May 20	BNOX	Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 17	BDX	BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
May 17	OTLK	Q2 2024 Outlook Therapeutics Inc Earnings Call
May 16	GLPG	Galapagos creates new subscription right plans
May 16	OTLK	Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
May 16	BDX	Becton, Dickinson and Company: Stagnating All Along
May 15	OTLK	Outlook Therapeutics reports Q2 results
May 15	OTLK	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
May 15	GLPG	Galapagos, BCA to collaborate on CAR-T cell therapy production
May 15	GLPG	Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
May 15	BDX	Women in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening

Monoclonal Antibodies: Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma cell (antibody secreting immune cell) lineages. Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one single monoclonal antibody to two epitopes.